The FebriDx test procedure: a) lance a finger; b) collect a hanging drop of blood; c) deliver blood sample to the cartridge; and d) press to add buffer.

of public health. From personalised to precision

healthcare, leaders must take a close look at outcomes, assess the effectiveness and viability of current protocols, and support the wave of change that has been lapping at the shores of healthcare in recent years. There have been many initiatives that purported to change the face of global health. Sadly, there remains a gulf between what has been achieved, what can be achieved, and what should be achieved. There is a siloed mentality to

healthcare. No matter the territory, each region appears to be looking after its own. With the spectre of local financial governance, unrealistic targets, competition and national pressures, it is no wonder that collaborative working has not brought about the sea change the proposed design will have aspired to deliver.

Enabling long-term change Global health crises should be enablers for change, but what has been achieved from previous pandemics? Where is the global community output? Information shared relates to mortality and not morality. Where is the global network whose mission statement is to revolutionise healthcare, work together for the common goal, offer transparency


and collaborate on the greatest of challenges? The tools are available, the support

on offer. It is time to take the initiative. The global healthcare community now needs to grasp the opportunity to forge partnerships with proven diagnostics manufacturers and distributors. Trust is a strong word with many connotations. This is the time for trust, and not a time for empty promises from leaders outside the healthcare landscape who will not fully understand the solutions they are presenting as the next ‘game changer’. Where a challenge exists there are teams of scientific and clinical staff willing to face it, push the boundaries of science, and deliver a viable solution. The first solution may not be the final solution in all cases, but the commitment to those solutions is unparalleled and should be widely acknowledged. The upscaling of laboratory functions during the SARS- CoV-2 pandemic has shown this is achievable, albeit with personal and professional sacrifices.

Understanding innovation and adoption This is where the development of new tests astounds and the healthcare industry and research organisation must be congratulated. The speed at which new assays can be added to existing or new

platforms is something to appreciate but also of which to be wary. In the wake of a global health crisis a large number of new tests can flood the health market, causing confusion among the adopters, and inadvertently arrest progress with regard to adoption. Tests released for emergency use only should be used with caution in a long- term clinical setting. Those tests lacking compelling performance data should be avoided. If the data do not give confidence to the user, then how can the best outcome be reliably delivered for the patient?

The clear message is to work with trusted and renowned companies. Those who publish their results, freely offer well- defined performance characteristics of their tests, and support implementation and interpretation of the new solution. Knowing the limitations of a new test is as valuable as knowing its best attribute. Working with the supplier to understand the full utility and application of a testing system is key to the success of translating that result into effective care.

Choosing the most effective and impactful solution One such solution that has stood out in the marketplace is FebriDx (developed and manufactured by Lumos Diagnostics and distributed by Una Health), a rapid


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62